Promising Prostate Cancer Treatment Combo Targets Hard-to-Treat Metastatic Tumors
TL;DR
RedHill Biopharma collaborates with Bayer AG to potentially enhance prostate cancer treatment, aiming to compete in the fast-growing prostate cancer drug market.
RedHill's opaganib, a selective inhibitor of SPHK2, may boost sensitivity to darolutamide, potentially overcoming resistance in men with mCRPC.
The collaboration between RedHill, Bayer, and Australian researchers offers hope for improving outcomes in advanced prostate cancer patients with limited treatment options.
Opaganib's anti-inflammatory and anti-cancer activities, along with its potential to induce metabolic stress in tumor cells, could revolutionize prostate cancer treatment.
Found this article helpful?
Share it with your network and spread the knowledge!
Medical researchers are exploring a potential breakthrough in treating advanced prostate cancer through a novel drug combination targeting treatment-resistant tumors. A Phase 2 clinical trial, funded by Bayer AG and the Ramsay Hospital Foundation, will examine whether combining RedHill's opaganib with Bayer's darolutamide can overcome androgen receptor pathway inhibition (ARPI) resistance.
Currently, approximately 20% of prostate cancer patients do not respond to standard androgen receptor signaling inhibitor therapies or develop resistance, leaving them with minimal treatment options. With global prostate cancer cases projected to double to 2.9 million annually by 2040, this research could significantly impact patient outcomes.
The clinical trial will investigate opaganib's potential to enhance darolutamide's effectiveness by targeting sphingolipid metabolic pathways. Researchers hypothesize that opaganib might induce metabolic stress in tumor cells and potentially restore sensitivity to androgen receptor pathway inhibition.
The 80-patient study will utilize a companion lipid biomarker test called PCPro to identify patients most likely to benefit from the treatment combination. A primary endpoint of improved 12-month radiographic progression-free survival will measure the intervention's effectiveness.
With only a 28% five-year relative survival rate for stage 4 prostate cancer patients, this research represents a critical effort to develop more targeted and effective treatment strategies for men with metastatic castrate-resistant prostate cancer.
Curated from News Direct
